TYLENOL COLD MULTI-SYMPTOM SEVERE LIQUID OTC
Generic Name and Formulations:
Acetaminophen 325mg, dextromethorphan HBr 10mg, guaifenesin 200mg, phenylephrine HCl 5mg; per 15mL; Citrus Burst liq.
McNeil Consumer Healthcare
Indications for TYLENOL COLD MULTI-SYMPTOM SEVERE LIQUID:
Nasal congestion, nonproductive cough, sore throat, headache, fever, minor aches and pains.
30mL every 4 hours; max 180mL/24 hours.
During or within 14 days of MAOIs. Concomitant other acetaminophen products.
Hepatic dysfunction. Cardiovascular disease. Hypertension. GI or GU obstruction. Thyroid disease. Diabetes. Asthma. Lower respiratory disorders. Pregnancy. Nursing mothers.
Analgesic + antitussive + expectorant + sympathomimetic.
See Contraindications. Hypertensive crisis with MAOIs. Increased risk of hepatotoxicity with ≥3 alcoholic drinks/day. β-blockers increase pressor effects of sympathomimetics. Antihypertensives antagonized.
Nervousness, dizziness, insomnia, hepatotoxicity (overdosage).
Endocrinology Advisor Articles
- Two Phases of C-Peptide Decline Identified in Type I Diabetes
- Incidence of Diabetes Influenced by Endocrine-Disrupting Chemicals in the Environment
- Subclinical Hypothyroidism: Controversies in Testing and Treatment
- Favorable Outcomes With Second-Generation Insulin Analogs in Type 2 Diabetes
- Assessment of Low-Dose Aspirin As Chemoprevention in Type 2 Diabetes
- Using Latent Class Trajectory Analysis to Determine Glucose Response Curve Patterns
- First CGM System With Implantable Glucose Sensor Approved
- Adjunctive Metformin for Insulin Resistance in T1D: A Clinical Perspective
- Risk for Below Knee Amputations With Canagliflozin vs Other Antihyperglycemic Agents
- Empagliflozin, Linagliptin Combination Therapy vs Linagliptin Monotherapy for Type 2 Diabetes
- Type 2 Diabetes and Alzheimer Disease: What's the Connection?
- Government and Industry Lead the Way in Funding USPSTF Systematic Reviews
- New Romosozumab BLA Includes Data from Additional Osteoporosis Trials
- Impact of Maternal Diabetes on Outcomes in Very Preterm, Very Low-Birth-Weight Infants
- Age-Related Differences in Manifestation of Cushing Disease Identified